Shots:

• BieGene to receive $650M up front- $1.55M as milestones along with royalties and retain rights to Tislelizumab in China & other countries. BeiGene has the option to co-detail Tislelizumab in NA
• Novartis to get the development & commercialization rights to Tislelizumab in the US- Canada- Mexico- EU- UK- Norway- Switzerland- Iceland- Liechtenstein- Russia- & Japan. Additionally- the companies have identified multiple Tislelizumab + Novartis’ therapy combination clinical trials in solid tumors
• Both parties have the freedom to conduct combination trials globally. Tislelizumab is an anti-PD-1 mAb- its 15 registration-enabling clinical trials underway in NSCLC and other solid tumors

 ­ Ref: Novartis | Image: Novartis